Peter van de Sande, Synaffix CEO

Lon­za shells out $107M cash to snap up Synaf­fix and its ADC plat­form

Af­ter lin­ing up a string of part­ner­ships over the years, Dutch an­ti­body-drug con­ju­gate spe­cial­ist Synaf­fix has found a new home: Lon­za, the con­tract de­vel­op­ment and man­u­fac­tur­ing gi­ant.

Lon­za is pay­ing about $107 mil­lion (€100 mil­lion) in cash to ac­quire Synaf­fix, with up to $64 mil­lion (€60 mil­lion) in “ad­di­tion­al per­for­mance-based con­sid­er­a­tion” on the ta­ble. Synaf­fix’s ADC tech plat­form will now be­come part of Lon­za’s of­fer­ing for bio­phar­ma clients, lend­ing its bio­con­ju­gate tech­nolo­gies to not just AD­Cs but al­so tar­get­ed gene ther­a­py, im­mune cell en­gagers and oth­er ap­pli­ca­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.